NASDAQ:OMER - Omeros Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.76 -0.24 (-1.20 %)
(As of 07/18/2018 05:01 AM ET)
Previous Close$20.00
Today's Range$19.61 - $20.69
52-Week Range$8.36 - $25.20
Volume398,900 shs
Average Volume1.13 million shs
Market Capitalization$1.01 billion
P/E Ratio-25.73
Dividend YieldN/A
Omeros logoOmeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-2.91
Current Ratio3.19
Quick Ratio3.18


Trailing P/E Ratio-25.73
Forward P/E Ratio-8.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.83 million
Price / Sales14.72
Cash FlowN/A
Price / CashN/A
Book Value($0.06) per share
Price / Book-329.33


EPS (Most Recent Fiscal Year)($0.79)
Net Income$-53,480,000.00
Net Margins-126.38%
Return on EquityN/A
Return on Assets-52.29%


Outstanding Shares48,290,000
Market Cap$1,014.64

The Truth About Cryptocurrencies

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.05. The biopharmaceutical company had revenue of $1.59 million for the quarter, compared to analysts' expectations of $2.08 million. Omeros's revenue was down 87.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) earnings per share. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

8 brokers have issued 12 month price objectives for Omeros' stock. Their predictions range from $4.00 to $75.00. On average, they anticipate Omeros' share price to reach $27.0013 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price. View Analyst Ratings for Omeros.

What is the consensus analysts' recommendation for Omeros?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a total firm value of roughly $2B to Omeros based on OMIDRIA ($806M) and OMS721 ($1.18B). This translates into a target of $34.00 per share, based on 58M fully-diluted shares outstanding as of end-1Q 2019." (6/28/2018)
  • 2. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (6/20/2018)
  • 3. Maxim Group analysts commented, "Prior to hitting the pass thru speed bump in January (and it’s just a speed bump), Omidria revenue grew to $22M in 3Q17. We expect these numbers to return in 4Q and for Omidria to grow with several factors to watch between now and then – 1Q expectations, getting back to pass-thru in October, impact of the VA and the healthy balance sheet." (5/7/2018)
  • 4. WBB Securities analysts commented, "We are therefore continuing our Strong Buy recommendation with a continued One-Year Target Price of $75. Pass-through enables physicians to prescribe and bill Medicare for the cost of designated drugs in addition to the fixed fee for which treatment is administered. The text of the bill states, “In the case of a drug or biological whose period of pass-through status under this paragraph ended on December 31, 2017, and for which payment under this subsection was packaged into a payment for a covered OPD service (or group of services) furnished beginning January 1, 2018, such pass- through status shall be extended for a 2-year period beginning on October 1, 2018.” While not a guarantee, we also believe that this is a logical next step to permanent reimbursement by CMS, which takes place with the vast majority of all drugs. OMIDRIA is a combination drug that is administered during intra-ocular surgery." (3/26/2018)

Who are some of Omeros' key competitors?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 55)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61)

Has Omeros been receiving favorable news coverage?

Headlines about OMER stock have trended somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros earned a media sentiment score of 0.08 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of of retail and institutional investors. Top institutional investors include DAVENPORT & Co LLC (0.11%), Bank of Montreal Can (0.09%), Nwam LLC (0.08%) and Mesirow Financial Investment Management Inc. (0.05%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC and Nwam LLC. Company insiders that have sold Omeros company stock in the last year include Marcia S Kelbon and Michael A Jacobsen. View Insider Buying and Selling for Omeros.

Which institutional investors are buying Omeros stock?

OMER stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $19.76.

How big of a company is Omeros?

Omeros has a market capitalization of $1.01 billion and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.

MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  727
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.